{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:06:24Z","timestamp":1784304384335,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007289","name":"Nanjing Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jiph.2026.103293","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T17:26:51Z","timestamp":1781458011000},"page":"103293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative metabolic safety of efavirenz-, dolutegravir-, and bictegravir-based antiretroviral regimens in HIV-infected adults: Evidence for weight-dependent lipid deterioration"],"prefix":"10.1016","volume":"19","author":[{"given":"Junzhong","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zere","family":"Aidynbek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bufeng","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yide","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5791-1123","authenticated-orcid":false,"given":"Yiting","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0097-6284","authenticated-orcid":false,"given":"Shanshan","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2026.103293_bib1","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3018(23)00028-0","article-title":"Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies","volume":"10","author":"Trickey","year":"2023","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiph.2026.103293_bib2","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1212\/WNL.0b013e31821670fb","article-title":"Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients","volume":"76","author":"Ciccarelli","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jiph.2026.103293_bib3","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s40121-024-00966-7","article-title":"Underlying neural mechanisms of cognitive improvement in fronto-striatal response inhibition in people living with HIV switching off efavirenz: a randomized controlled BOLD fMRI trial","volume":"13","author":"Oomen","year":"2024","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiph.2026.103293_bib4","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1007\/s40121-025-01218-y","article-title":"Associated factors of cognitive frailty in people living with HIV aged 50 and older: a cross-sectional study","volume":"14","author":"Xu","year":"2025","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiph.2026.103293_bib5","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2023.2295435","article-title":"Blood glucose level and serum lipid profiles among people living with HIV on dolutegravir-based versus efavirenz-based cART; a comparative cross-sectional study","volume":"55","author":"Jemal","year":"2023","journal-title":"Ann Med"},{"key":"10.1016\/j.jiph.2026.103293_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1436123","article-title":"The clinical indexes and immunological status of HIV\/AIDS patients undergoing different highly active antiretroviral treatments","volume":"14","author":"Wan","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jiph.2026.103293_bib7","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1007\/s40121-023-00879-x","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide versus dolutegravir plus lamivudine for switch therapy in patients with HIV-1 infection: a real-world cohort study","volume":"12","author":"Gan","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiph.2026.103293_bib8","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral society\u2013USA panel","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jiph.2026.103293_bib9","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","article-title":"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials","volume":"7","author":"Orkin","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiph.2026.103293_bib10","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(24)00030-4","volume":"11","author":"Mills","year":"2024","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiph.2026.103293_bib11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jama.2024.24543","article-title":"Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the international antiviral society\u2013USA panel","volume":"333","author":"Gandhi","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jiph.2026.103293_bib12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3389\/fendo.2018.00705","article-title":"The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality","volume":"9","author":"Kumar","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jiph.2026.103293_bib13","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1038\/s41598-024-53701-0","article-title":"Trends of body mass index changes among adults on antiretroviral therapy in northwest Ethiopia: a longitudinal data analysis","volume":"14","author":"Bantie","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiph.2026.103293_bib14","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","volume":"7","author":"Venter","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiph.2026.103293_bib15","doi-asserted-by":"crossref","first-page":"758","DOI":"10.7326\/M20-4853","article-title":"Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: a cohort study","volume":"174","author":"Surial","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jiph.2026.103293_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101412","article-title":"Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy \u2013 a systematic literature review and network meta-analysis","volume":"48","author":"Kanters","year":"2022","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.jiph.2026.103293_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25702","article-title":"Weight gain before and after switch from TDF to TAF in a U.S. cohort study","volume":"24","author":"Mallon","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.jiph.2026.103293_bib18","article-title":"Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide (TAF) in people with human immunodeficiency virus (HIV)","volume":"79","author":"Damas","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2026.103293_bib19","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/hiv.13488","article-title":"Weight gain following the single substitution of tenofovir disoproxil fumarate by tenofovir alafenamide in HIV -infected people from the French dat\u2019 AIDS cohort: a propensity score-matched analysis","volume":"24","author":"Hocqueloux","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.jiph.2026.103293_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2025.108321","article-title":"Dolutegravir\/lamivudine versus bictegravir\/emtricitabine\/tenofovir alafenamide fumarate: real-world assessment of effectiveness and weight gain in na\u00efve people living with HIV of Asian OrigiN (DRAGON)","volume":"164","author":"Yang","year":"2026","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jiph.2026.103293_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.106020","article-title":"Bictegravir alters glucose tolerance in vivo and causes hepatic mitochondrial dysfunction","volume":"231","author":"Garc\u00eda-Mart\u00ednez","year":"2024","journal-title":"Antivir Res"},{"key":"10.1016\/j.jiph.2026.103293_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.670566","article-title":"Contribution of adipose tissue to the chronic immune activation and inflammation associated with HIV infection and its treatment","volume":"12","author":"Bourgeois","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jiph.2026.103293_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10142-025-01585-2","article-title":"The miRNomics of antiretroviral therapy-induced obesity","volume":"25","author":"Majumdar","year":"2025","journal-title":"Funct Integr Genom"},{"key":"10.1016\/j.jiph.2026.103293_bib24","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2026.103293_bib25","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/jac\/dkae238","article-title":"Low CD4 counts predict excessive weight gains during first-line treatment for HIV","volume":"79","author":"Hill","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2026.103293_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25484","article-title":"Weight gain among treatment-na\u00efve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada","volume":"23","author":"Bourgi","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.jiph.2026.103293_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiph.2024.102630","article-title":"Effect of dolutegravir on weight changes and lipid profile compared with efavirenz in people living with HIV: a retrospective cohort study","volume":"18","author":"Setpakdee","year":"2025","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.jiph.2026.103293_bib28","article-title":"The effects of ART on the dynamics of lipid profiles in chinese han HIV-infected patients: comparison between NRTI\/NNRTI and NRTI\/INSTI","volume":"11","author":"Liu","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.jiph.2026.103293_bib29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/cid\/ciad545","article-title":"Weight gain after antiretroviral therapy initiation and subsequent risk of metabolic and cardiovascular disease","volume":"78","author":"Bares","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2026.103293_bib30","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1093\/jac\/dkaf319","article-title":"Pharmacokinetics of rifampicin and isoniazid in patients with HIV\u2013tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292\u2013RIFAVIRENZ sub-study","volume":"80","author":"Gel\u00e9","year":"2025","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034126001656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034126001656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:28:34Z","timestamp":1784302114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034126001656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1876034126001656"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2026.103293","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative metabolic safety of efavirenz-, dolutegravir-, and bictegravir-based antiretroviral regimens in HIV-infected adults: Evidence for weight-dependent lipid deterioration","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2026.103293","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}],"article-number":"103293"}}